Return to content in this issue

 

Efficacy of mepolizumab in patients with concomitant severe eosinophilic asthma and severe chronic urticaria: an example of personalized medicine?

Antonicelli L1, Tontini C2, Garritani MS1, Piga MA3, Bilò MB1,3

1SOSD Allergologia, Dipartimento di Medicina Interna, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona (Italy)
2Lydia Becker Institute for Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (United Kingdom)
3Dipartimento di Scienze Cliniche e Molecolari, Universita’ Politecnica delle Marche, Ancona (Italy)

J Investig Allergol Clin Immunol 2022; Vol. 32(5)
doi: 10.18176/jiaci.0770

Key words: Efficacy, Mepolizumab, Personalized medicine, Severe eosinophilic asthma, Severe chronic urticaria